ClinicalTrials.gg
RecruitingNCT07388602Updated Feb 5, 2026

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

A Phase 3 interventional study of SCTC21C and Bortezomib in Amyloidosis, sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies in Amyloidosis with a site in China — 21 open to participants now, 25 under way, 3 of them phase 3. Amyloidosis · China.

Planned enrollment
7th of 24
90 · median 53
Started
2026
with 2 others
Phase 3
5 of 32
2 open now
Primary completion
2027-12
later than 11 of 24 live
Registered
29th of 32
by date

Among the 32 studies in Amyloidosis with a site in China, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 11 of the 24 other live ones, and was the 29th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

21 of the 32 studies in Amyloidosis with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Amyloidosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Read the detailed description

This study comprises two phases: Part 1 is the safety run in, while Part 2 is a randomized, controlled, open-label, multicenter study. Both parts are divided into three stages: the screening period (up to 28 days before first dose/randomization), the treatment period (from Cycle 1 [28 days] Day 1 and continues until disease progression or unacceptable toxicity), and the follow-up period (Postintervention). Safety endpoints include treatment-emergent adverse events , treatment-related adverse events, serious adverse events, clinical laboratory tests, vital signs, physical examinations, electrocardiograms , etc. Efficacy endpoints include Overall Complete Hematologic Response (CHR),objective response rate (ORR), Hematologic Very Good Partial Response (VGPR) or Better Rate, Overall Survival (OS).

03

Conditions studied

  • Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in congo red stained tissue specimens or characteristic electron microscopy appearance;
  • of amyloid light-chain (AL) amyloidosis;
  • One or more organs impacted by AL amyloidosis according to consensus guidelines
  • (ECOG) Performance Status (PS) 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for AL amyloidosis;
  • Other amyloidosis;
  • Uncontrolled infection.
  • Subjects with conditions that may affect safety or efficacy assessments include, but are not limited to, cardiovascular, respiratory, endocrine/metabolic, immune system, hepatic, gastrointestinal (such as gastrointestinal bleeding, perforation, ulcers, etc.), and malignant neoplasms, and are deemed by the investigator.
  • Subjects who have undergone major surgery or experienced significant trauma within 4 weeks prior to the first use of the drug, or who require elective surgery during the trial period.
  • Received a live or attenuated vaccine within 30 days prior to the first dose; Female subjects who are currently breastfeeding.
  • Subjects with mental disorders or poor compliance, or other circumstances deemed unsuitable for participation in this study by other investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    SCTC21C + VCd (S-VCd)

    Drug: SCTC21C · Drug: Bortezomib · Drug: Dexamethasone · Drug: Cyclophosphamide

  • Active comparator
    VCd

    Drug: Bortezomib · Drug: Dexamethasone · Drug: Cyclophosphamide

Interventions

  • Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous

  • Pharmaceutical form: Lyophilized powder for injection; Route of administration: Subcutaneous

  • Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous

  • Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Complete Hematologic Response (CHR)

    Overall CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria.

    Time frame: Up to approximately 50 months after the First Participant In (FPI)

Secondary outcomes

  1. Major Organ Deterioration Progression-Free Survival (MOD-PFS)

    MOD-PFS was defined as duration from the date of randomization to either hematologic progression, or major organ deterioration (clinical manifestation of cardiac failure or renal failure), or death, whichever occurred first.

    Time frame: Up to approximately 50 months after the FPI

  2. Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months

    CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria.

    Time frame: Month 6

  3. Duration of Complete Hematologic Response (CHR)

    Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased.

    Time frame: Up to approximately 50 months after the FPI

  4. Hematologic Very Good Partial Response (VGPR) or Better Rate

    Hematologic VGPR or Better Rate was defined as percentage of participants who achieved hematologic Complete response (CR) or VGPR.

    Time frame: Up to approximately 50 months after the FPI

  5. Overall Survival (OS)

    Overall survival (OS) was measured from the date of randomization to the date of the participant's death.

    Time frame: Up to approximately 50 months after the FPI

  6. Adverse Events

    Treatment-emergent adverse events/serious adverse events

    Time frame: Up to approximately 50 months after the FPI

Other outcomes

  1. PRO: EQ-5D-5L

    Health state utility and health status will be assessed using the European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)

    Time frame: Up to approximately 50 months after the FPI

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 74. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 5, 2026
StartActual
Jan 8, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07388602
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Jan 8, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD38 Monoclonal Antibody SCTC21C

Start the discussion